ArticleScientific reports2026
miR-542-3p targets TTF1 to regulate proliferation, invasion, and migration of lung adenocarcinoma via the MAPK signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer has the highest incidence and mortality rates among all malignant tumors worldwide, with poor treatment outcomes and a high risk of postoperative recurrence. Currently, more than 50% of lung cancer cases are lung adenocarcinoma, which is characterized by early metastasis, recurrence, and therapeutic challenges. However, lung adenocarcinoma underlying nosogenesis mechanisms remain unclear. miRNAs are small non-coding RNAs that play crucial roles in regulating cell differentiation, proliferation, apoptosis, and other processes. They exert biological functions by suppressing the expression of target genes and have emerged as key players in cancer diagnosis, treatment, and prognosis evaluation. Numerous studies have shown that miR-542-3p is aberrantly expressed in various tumors and can either promote or inhibit the development and progression of multiple malignancies. This study aims to investigate the expression of miR-542-3p in lung adenocarcinoma and its effects on the biological behavior of lung adenocarcinoma cells, as well as to analyze the relationship between miR-542-3p, TTF1, and the MAPK pathway, with the goal of identifying novel therapeutic targets for lung adenocarcinoma. The results demonstrate that miR-542-3p is lower expressed in lung adenocarcinoma, where it directly regulates TTF1 expression and subsequently inhibits the MAPK signaling pathway indirectly via TTF1 downregulation, thereby reducing the proliferation, migration, and invasion capabilities of lung adenocarcinoma cells and suppressing tumor growth. This study is the first to reveal the critical role of the miR-542-3p/TTF1/MAPK regulatory axis in lung adenocarcinoma cell proliferation, migration, invasion, and tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.